A Phase 1 Study of Mixed Bacteria Vaccine (MBV) in Patients With Tumors Expressing NY-ESO-1 Antigen
- First Posted Date
- 2008-02-26
- Last Posted Date
- 2022-10-25
- Lead Sponsor
- Ludwig Institute for Cancer Research
- Target Recruit Count
- 17
- Registration Number
- NCT00623831
- Locations
- 🇩🇪
Krankenhaus Nordwest, Frankfurt, Germany
Phase 1 Study of NY-ESO-1 Overlapping Peptides in Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
- First Posted Date
- 2008-02-15
- Last Posted Date
- 2022-10-12
- Lead Sponsor
- Ludwig Institute for Cancer Research
- Target Recruit Count
- 28
- Registration Number
- NCT00616941
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Study of ADI-PEG 20 in Patients With Advanced Melanoma
- First Posted Date
- 2007-08-24
- Last Posted Date
- 2022-10-25
- Lead Sponsor
- Ludwig Institute for Cancer Research
- Target Recruit Count
- 31
- Registration Number
- NCT00520299
- Locations
- 🇺🇸
NYU Cancer Institute, New York, New York, United States
🇺🇸Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Study of Safety and Functional Imaging of cG250 and Sunitinib in Patients With Advanced Renal Cell Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2007-08-24
- Last Posted Date
- 2022-10-12
- Lead Sponsor
- Ludwig Institute for Cancer Research
- Target Recruit Count
- 8
- Registration Number
- NCT00520533
- Locations
- 🇦🇺
Austin Health (Ludwig Institute Oncology Unit), Heidelberg, Victoria, Australia
Study of NY-ESO-1 ISCOMATRIX® in Patients With Measurable Stage III or IV Melanoma
- Conditions
- Interventions
- First Posted Date
- 2007-08-20
- Last Posted Date
- 2022-10-25
- Lead Sponsor
- Ludwig Institute for Cancer Research
- Target Recruit Count
- 46
- Registration Number
- NCT00518206
- Locations
- 🇦🇺
Austin Health (Ludwig Institute Oncology Unit), Heidelberg, Victoria, Australia
🇦🇺Peter MacCallum Cancer Institute, East Melbourne, Victoria, Australia
NY-ESO-1 Protein With Montanide and CpG 7909 as Cancer Vaccine in Several Tumors
- First Posted Date
- 2006-03-07
- Last Posted Date
- 2022-10-10
- Lead Sponsor
- Ludwig Institute for Cancer Research
- Target Recruit Count
- 22
- Registration Number
- NCT00299728
- Locations
- 🇺🇸
NYU Clinical Cancer Center, New York, New York, United States
🇺🇸NY Presbyterian- Columbia, New York, New York, United States
Biodistribution Study of CMD-193 in Patients With Advanced Tumours Expressing the Lewis-Y Antigen
- First Posted Date
- 2006-02-17
- Last Posted Date
- 2022-10-10
- Lead Sponsor
- Ludwig Institute for Cancer Research
- Target Recruit Count
- 9
- Registration Number
- NCT00293215
- Locations
- 🇦🇺
Cancer Care Services, Dept. of Medical Oncology, Royal Brisbane and Women's Hospital, Herston, Queensland, Australia
🇦🇺Ludwig Institute Tumor Targeting Program, Austin Health, Heidelberg (Melbourne), Victoria, Australia
Immunization With NY-ESO-1 Protein Combined With CpG 7909 in Patients With Prostate Cancer
- First Posted Date
- 2006-02-15
- Last Posted Date
- 2023-10-04
- Lead Sponsor
- Ludwig Institute for Cancer Research
- Target Recruit Count
- 15
- Registration Number
- NCT00292045
- Locations
- 🇩🇪
Krankenhaus Nordwest, Frankfurt, Germany
🇨🇭Universitätsspital Zürich, Zurich, Switzerland
Safety and Immunogenicity of CHP-HER2 and CHP-NY-ESO-1 Protein With OK-432 in Antigen-Expressing Cancers
- Conditions
- First Posted Date
- 2006-02-14
- Last Posted Date
- 2009-03-03
- Lead Sponsor
- Ludwig Institute for Cancer Research
- Target Recruit Count
- 9
- Registration Number
- NCT00291473
- Locations
- 🇯🇵
Mie University Hospital, Tsu, Mie, Japan
111In-ch806 in Patients With Advanced Tumours Expressing the 806 Antigen
- First Posted Date
- 2006-02-14
- Last Posted Date
- 2022-10-10
- Lead Sponsor
- Ludwig Institute for Cancer Research
- Target Recruit Count
- 8
- Registration Number
- NCT00291447
- Locations
- 🇦🇺
Ludwig Institute Tumor Targeting Program, Austin Health, Heidelberg, Victoria, Australia